摘要
目的采用多重巢式PCR（multi—nest PCR）方法，以TEL-AML1融合基因为靶分子，研究TEL-AML1阳性儿童急性淋巴细胞性白血病（Acute Lymphoblastic Leukemia，ALL）的临床特点及生存分析。方法以20例TEL-AML1阳性患儿为研究对象，选取同期初诊的融合基因阴性的52名患儿为对照，研究两组患儿初诊临床特征并比较TEL-AML1阳性和阴性患儿的无事故生存率（Event Free Survival，EFS）。所有结果用SPSS10．0统计软件包处理。结果TEL-AML1阳性患儿多伴随白细胞〈25×10^9/L、年龄在1至9岁之间、B系淋巴细胞表型等临床特征；TEL-AML1阳性患儿的5年EFS为91％，对照组为87％，两者无显著性差异。结论TEL-AML1融合基因携带者多伴随提示预后良好的临床特征；TEL-AML1融合基因阳性不是影响预后的独立因素。
Objective To investigate the clinical and survival characteristics of TEL-AML1 in childhood acute lymphoblastie leukemia （ALL） by the method of multi-nest PCR. Methods Two groups, in which one was twenty children with TEL-AML1 ALL and another was fifty-two negative ones, were analyzed to compare the newly diagnosed clinical features and the event free survival （EFS） between TEL-AML1 ALL and non-TEL-AML1 ALL. The SPSS 10.0 software package was used to analyze the data. Results Clinical features, such as lower peripheral WBC count, favorable ages, low risk of relapse and B lineage phenotype were characterized with TEL-AML1. Five-year EFS of the TEL-AML1 positive and negative groups were 91% and 87% respectively, and there was no significant difference between these two groups. Conclusions The patients with TEL-AML1 are often accompanied with clinical features of a favorable prognosis. TEL-AML1 is not an independent prognostic factor.
出处
《临床医学工程》
2009年第8期60-62,共3页
Clinical Medicine & Engineering
